Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.

Phares TW, May AD, Genito CJ, Hoyt NA, Khan FA, Porter MD, DeBot M, Waters NC, Saudan P, Dutta S.

Malar J. 2017 Mar 13;16(1):115. doi: 10.1186/s12936-017-1766-3.

2.

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response.

Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V.

J Transl Med. 2017 Jan 3;15(1):1. doi: 10.1186/s12967-016-1111-6.

3.

Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.

van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah AM, Diro E.

PLoS Negl Trop Dis. 2016 Mar 3;10(3):e0004495. doi: 10.1371/journal.pntd.0004495. eCollection 2016 Mar. Review.

4.

CpG Oligodeoxynucleotide Inhibits Cockroach-Induced Asthma via Induction of IFN-γ⁺ Th1 Cells or Foxp3⁺ Regulatory T Cells in the Lung.

Kim DH, Sohn JH, Park HJ, Lee JH, Park JW, Choi JM.

Allergy Asthma Immunol Res. 2016 May;8(3):264-75. doi: 10.4168/aair.2016.8.3.264.

5.

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.

Kachura MA, Hickle C, Kell SA, Sathe A, Calacsan C, Kiwan R, Hall B, Milley R, Ott G, Coffman RL, Kanzler H, Campbell JD.

J Immunol. 2016 Jan 1;196(1):284-97. doi: 10.4049/jimmunol.1501903. Epub 2015 Nov 25.

6.

Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.

Aoshi T, Haseda Y, Kobiyama K, Narita H, Sato H, Nankai H, Mochizuki S, Sakurai K, Katakai Y, Yasutomi Y, Kuroda E, Coban C, Ishii KJ.

J Immunol Res. 2015;2015:316364. doi: 10.1155/2015/316364. Epub 2015 Aug 25.

7.

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.

Schmidt M, Hagner N, Marco A, König-Merediz SA, Schroff M, Wittig B.

Nucleic Acid Ther. 2015 Jun;25(3):130-40. doi: 10.1089/nat.2015.0533. Epub 2015 Mar 31.

8.

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.

Martinez P, Sundling C, O'Dell S, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Rep. 2015 Mar 12;5:8925. doi: 10.1038/srep08925.

9.

Nonhuman primate models for HIV/AIDS vaccine development.

Sui Y, Gordon S, Franchini G, Berzofsky JA.

Curr Protoc Immunol. 2013 Oct 1;102:Unit 12.14.. doi: 10.1002/0471142735.im1214s102. Review.

10.

A review of adjuvants for Leishmania vaccine candidates.

Mutiso JM, Macharia JC, Gicheru MM.

J Biomed Res. 2010 Jan;24(1):16-25. doi: 10.1016/S1674-8301(10)60004-8.

11.

Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.

Kobayashi N, Hong C, Klinman DM, Shirota H.

J Immunol. 2013 Feb 15;190(4):1882-9. doi: 10.4049/jimmunol.1201063. Epub 2013 Jan 7.

12.

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, Ishii KJ, Horii T.

Hum Vaccin Immunother. 2013 Feb;9(2):283-90. Epub 2013 Jan 4.

13.

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

McBurney SP, Landucci G, Forthal DN, Ross TM.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72. doi: 10.1089/AID.2011.0351. Epub 2012 Mar 21.

14.

Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation.

Gujer C, Sundling C, Seder RA, Karlsson Hedestam GB, Loré K.

Immunology. 2011 Nov;134(3):257-69. doi: 10.1111/j.1365-2567.2011.03484.x.

15.

CpG DNA as a vaccine adjuvant.

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM.

Expert Rev Vaccines. 2011 Apr;10(4):499-511. doi: 10.1586/erv.10.174. Review.

16.

The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides.

Yamamoto M, Sato T, Beren J, Verthelyi D, Klinman DM.

Biomaterials. 2011 Jun;32(18):4238-42. doi: 10.1016/j.biomaterials.2011.02.043. Epub 2011 Mar 21.

17.

Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke.

Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD, Hobbs TR, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2011 May;31(5):1229-42. doi: 10.1038/jcbfm.2011.6. Epub 2011 Feb 2.

18.

Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.

Verthelyi D, Wang V.

PLoS One. 2010 Dec 22;5(12):e15252. doi: 10.1371/journal.pone.0015252.

19.

Accelerated wound healing mediated by activation of Toll-like receptor 9.

Sato T, Yamamoto M, Shimosato T, Klinman DM.

Wound Repair Regen. 2010 Nov-Dec;18(6):586-93. doi: 10.1111/j.1524-475X.2010.00632.x. Epub 2010 Oct 13.

20.

Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Vagenas P, Williams VG, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard JL, Gettie A, Robbiani M.

J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):433-42. doi: 10.1097/QAI.0b013e3181b880f3.

Supplemental Content

Support Center